Clinical trials: HTN
Ocular Hypertension, Open-angle Glaucoma
Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol.
- Trial name
- NCT01306461
- Testing
- Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol
- Where
- Hungary
- Volunteers
- 401 people
- Sponsor
- Santen Oy
Diabetes, Hypertension
Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension
We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo…
- Trial name
- QUALITY (NCT00795262)
- Testing
- Quinapril (Accupril) plus Alpha Lipoic Acid, accupril, alpha lipoic acid
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- InVasc Therapeutics, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension…
- Trial name
- TRITON (NCT03850782)
- Testing
- Bimatoprost (SR)
- Where
- 108 sites in United States, Argentina and 14 more
- Volunteers
- 515 people
- Sponsor
- AbbVie
Heart Failure, Pulmonary Arterial Hypertension
Non-invasive Pulmonary Artery Prediction (ADOPTS)
A proprietary machine-learning algorithm has been developed to model continuous pulmonary artery pressure (PAP), a physiologic marker of cardiopulmonary function.
- Trial name
- ADOPTS (NCT05641675)
- Testing
- right heart catheterization
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Silverleaf Medical Sciences INC
Hypertension
A Study to Evaluate ART101 in Adult Participants With Hypertension
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, Pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of ART101 administered via subcutaneous…
- Trial name
- NCT06780033
- Testing
- ART-101 - SAD
- Where
- 3 sites in Australia
- Volunteers
- 1 people
- Sponsor
- Arnatar Therapeutics, Inc.
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Glaucoma, Open-Angle
Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent Supra
Open Angle Glaucoma Subjects with Cataract treated with Cataract Surgery plus one trabecular micro-bypass stent and one suprachoroidal stent
- Trial name
- NCT03255785
- Testing
- Cataract surgery plus one iStent and one iStent Supra implanted
- Where
- Armenia
- Volunteers
- 15 people
- Sponsor
- Glaukos Corporation
Hypertension
A Controlled Study to Investigate the Effect of Multi-wave Light Emitting Diode (LED) Bed on Blood Pressure and Endothelial Function
The objective of this multi-center study is to investigate the effect of a multi-wave LED light bed on blood pressure and endothelial function in pre-hypertensive and mildly hypertensive adults.
- Trial name
- NCT04006158
- Testing
- LED bed
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- LED Intellectual Properties, LLC
Primary Hypertension
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
- Trial name
- NCT06884085
- Testing
- Co-administration of AD-227A and AD-227B, Administration of AD-227
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension
The PK/PD Study of SHR0532 Tablets in Healthy Subjects
In the last four decades, several classes of diuretics have been the first line option for the therapy of widespread hypertension. However, all the classes of diuretics cause alteration of potassium homeostasis.
- Trial name
- NCT03645278
- Testing
- SHR0532
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Essential Hypertension
A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetic, pharmacodynamic characteristics and the safety after administration by doses of "BR1400-1", "BR1400-2", "BR1400-3" in healthy volunteers
- Trial name
- NCT06889064
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
This randomized, double-blind, multicenter phase 3 clinical trial evaluated the efficacy and safety of KDF1901, a single-pill triple combination of valsartan, amlodipine, and chlorthalidone, in patients with essential…
- Trial name
- NCT07116863
- Testing
- KDF1901-R0, KDF1901-L, KDF1901
- Where
- 2 sites in South Korea
- Volunteers
- 286 people
- Sponsor
- Kyungdong Pharmaceutical Co., Ltd.
Glaucoma, Ocular Hypertension
Use of an Ocular Telemetry Sensor in Diamox Treated Patients
A soft contact lens integrating a Sensor is placed on subjects with high intraocular pressure (IOP) after administration of an IOP-lowering drug to investigate the device's capacity to detect the induced IOP reduction.
- Trial name
- NCT01028664
- Testing
- SENSIMED Triggerfish
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Sensimed AG
Pulmonary Hypertension
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
- Trial name
- NCT00091598
- Testing
- Ambrisentan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 372 people
- Sponsor
- Gilead Sciences
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Hypertension, Resistant Hypertension
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
- Conditions
- Hypertension, Resistant Hypertension, Uncontrolled Hypertension
- Trial name
- NCT07833098
- Testing
- VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Hypertension
Amlodipine 10mg Drug Use Investigation
In this survey, to collect the safety and efficacy information in the subjects who have been treated with amlodipine 5mg at least 4 weeks in daily practice.
- Trial name
- ENTER10 (NCT01252563)
- Testing
- Amlodipine
- Volunteers
- 14,141 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
This study will assess the effectiveness and safety of different combination antihypertensive treatments in patients with severe hypertension
- Trial name
- NCT00171535
- Testing
- valsartan/amlodipine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Novartis
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Hypertension
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
This trial will compare valsartan and amlodipine combination therapies to valsartan and amlodipine monotherapy,and placebo for treating patients with hypertension
- Trial name
- NCT00409643
- Testing
- valsartan+amlodipine combination, valsartan, amlodipine
- Where
- 2 sites in United States, Germany
- Volunteers
- 1,259 people
- Sponsor
- Novartis